DOCSLIB.ORG

Cdc25 Inhibition and Cell Cycle Arrest by a Synthetic Thioalkyl Vitamin K Analogue1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cdc25 Inhibition and Cell Cycle Arrest by a Synthetic Thioalkyl Vitamin K Analogue1 [CANCER RESEARCH 60, 1317–1325, March 1, 2000] Cdc25 Inhibition and Cell Cycle Arrest by a Synthetic Thioalkyl Vitamin K Analogue1 Kenji Tamura, Eileen C. Southwick, Jeffrey Kerns, Katherine Rosi, Brian I. Carr, Craig Wilcox, and John S. Lazo2 Departments of Pharmacology [K. T., E. C. S., J. S. L.], Chemistry [J. K., K. R., C. W.], and Surgery [B. C.], University of Pittsburgh, Pittsburgh, Pennsylvania 15261, and Second Department of Internal Medicine [K. T.], Hiroshima University School of Medicine, Hiroshima 734, Japan ABSTRACT suggesting that unlike vitamin K3, its inhibition is mediated by sulf- hydryl arylation rather than oxidative stress (8). One proposed site for A synthetic vitamin K analogue, 2-(2-mercaptoethanol)-3-methyl-1,4- interaction is the catalytic cysteine(s) found in protein tyrosine phos- naphthoquinone or compound 5 (Cpd 5), was found previously to be a phatases that regulate cell proliferation (2). potent inhibitor of tumor cell growth. We now demonstrate that Cpd 5 Protein tyrosine phosphatases that have an essential role in cell arrested cell cycle progression at both G1 and G2-M. Because of the potential arylating activity of Cpd 5, it might inhibit Cdc25 phosphatases, cycle progression include the Cdc25 phosphatases, which activate which contain a cysteine in the catalytic site. To test this hypothesis, we Cdks. In mammalian cells, Cdc25 phosphatases are encoded by a examined the inhibitory activity of Cpd 5 against several cell cycle- multigene family consisting of Cdc25A, Cdc25B, and Cdc25C (9– relevant protein tyrosine phosphatases and found that Cpd 5 was a potent, 11). Each Cdc25 homologue controls distinct aspects of cell cycle selective, and partially competitive inhibitor of Cdc25 phosphatases. Fur- progression. Cdc25C dephosphorylates and activates the mitotic ki- thermore, Cpd 5 caused time-dependent, irreversible enzyme inhibition, nase Cdc2/cyclin B, which is required for entry into mitosis (12). consistent with arylation of the catalytic cysteine in Cdc25. Treatment of Cdc25A is important for entry into S-phase (13), whereas Cdc25B is cells with Cpd 5 blocked dephosphorylation of the Cdc25C substrate, essential for preinitiating G -M transition and S-phase progression Cdc2, and its kinase activity. Cpd 5 enhanced tyrosine phosphorylation of 2 (14). Cdc25A and Cdc25B have oncogenic properties in cells that both potent regulators of G1 transition, i.e., Cdk2 and Cdk4, and de- creased the phosphorylation of Rb, an endogenous substrate for Cdk4 have mutated Ha-ras or loss of Rb1, the Rb susceptibility gene (15). kinase. Furthermore, close chemical analogues that lacked in vitro Cdc25 Cdc25A and Cdc25B are transcriptional targets of the c-myc oncogene inhibitory activity failed to block cell cycle progression and Cdc2 kinase (16) and are overexpressed in several tumor types and may reflect activity. Cpd 5 did not alter the levels of p53 or the endogenous cyclin- poor prognosis (15, 17–19). Unfortunately, potent and selective in- dependent kinase inhibitors, p21 and p16. Our results support the hy- hibitors of Cdc25 phosphatases are currently unavailable but would be pothesis that the disruption in cell cycle transition caused by Cpd 5 was attractive candidates as potential anticancer agents. attributable to intracellular Cdc25 inhibition. This novel thioalkyl K In human hepatoma cells, vitamin K3 induces hyperphosphoryla- vitamin analogue could be useful for cell cycle control studies and may tion of p34cdc2 (Cdc2) kinase and decreases the protein tyrosine provide a valuable pharmacophore for the design of future therapeutics. phosphatase activity in cell lysates (20). Vitamin K3 and other naph- thoquinone analogues inhibit Cdc25A in vitro, and one of these INTRODUCTION analogues has been shown to cause G1 arrest (21). The mechanism by The vitamin K family of molecules comprises the natural forms which the potent redox-deficient thioalkyl K vitamin analogue Cpd 5 inhibits cell growth is not known, although inhibition of Cdc25 has vitamin K1 (phylloquinone) and vitamin K2 (menaquinones) and the been hypothesized (2). Thus, we have examined the actions of Cpd 5 synthetic form vitamin K3 (menadione). These naphthoquinone-con- taining molecules inhibit tumor cell growth in culture, with vitamin and two other vitamin K analogues on protein tyrosine phosphatases, including Cdc25A, Cdc25B, and Cdc25C, as well as their antiprolif- K3 being more potent than either vitamin K1 or K2 (1). Vitamin K3 exhibits low toxicity to animals (2, 3) and can enhance the antipro- erative and cell cycle checkpoint activity. liferative effects of other clinically used anticancer agents (4), al- though it is toxic to humans (5). The growth-inhibitory actions of MATERIALS AND METHODS vitamin K3 have been ascribed to both sulfhydryl arylation and oxidative stress because of redox cycling (6, 7). We previously 3 Materials and Antibodies. tsFT210 cells were a generous gift from Dr. synthesized and characterized a thioalkyl K vitamin analogue, Cpd 5 Chris Norbury (Oxford University, Oxford, United Kingdom) and were main- (Fig. 1), with superior growth-inhibitory activity that also rapidly tained for no longer than 30 passages as described elsewhere (22). The enhances cellular protein tyrosine phosphorylation and causes apop- anti-Cdc2 (SC 54), anti-Cdk2 (SC 163G), anti-Cdk4 (SC 601G), anti-cyclin D1 tosis (8). The antiproliferative and antiphosphatase activity of Cpd 5 (SC 6281), anti-cyclin E (SC 481), anti-p53 (SC 1312), anti-p21 (SC 3976), is antagonized by exogenous thiols but not by nonthiol antioxidants, and anti-p16 (SC 1207) antibodies were purchased from Santa Cruz Biotech- nology (Santa Cruz, CA). Agarose conjugate of each antibody was used for immunoprecipitation. Anti-cyclin A antibody was purchased from Oncogene Received 8/26/99; accepted 1/6/00. The costs of publication of this article were defrayed in part by the payment of page Research Product (Cambridge, MA). Anti-phosphotyrosine antibody was pur- charges. This article must therefore be hereby marked advertisement in accordance with chased from Upstate Biotechnology (Lake Placid, NY). Phospho-Rb antibody 18 U.S.C. Section 1734 solely to indicate this fact. and Rb antibody were purchased from New England Biolabs, Inc. (Beverly, 1 Supported in part by Army Breast Grant DAMD17-97-1-7229, the Fiske Drug MA), and anti-GAPDH antibody was purchased from Chemicon International, Discovery Fund, and USPHS NIH Grants CA 78039 and CA 82723. 2 To whom requests for reprints should be addressed, at Department of Pharmacology, Inc. (Temecula, CA). Histone H1 was obtained from Boehringer Mannheim Biomedical Science Tower E-1340, University of Pittsburgh, Pittsburgh, PA 15261. Co. (Indianapolis, IN). [␥-32P]ATP (10 mCi/ml) was from Amersham Life Phone: (412) 648-9319; Fax: (412) 648-2229; E-mail: [email protected]. Science, Inc. (Arlington Heights, IL). 3 The abbreviations used are: Cpd 5, compound 5, 2-(2-mercaptoethanol)-3-methyl- Chemical Syntheses. To synthesize Cpd 5, we added 1,8-diaza- 1,4-naphthoquinone; Cpd 16, 2-methyl-3-(1-oxyoctyl)-1,4-naphthoquinone; Cpd 22, 2-hydroxy-3-methyl-1,4-naphthoquinone (phthiocol); THF, tetrahydrofuran; NMR, nu- bicyclo[5.4.0]un-dec-7-ene (0.07 ml, 0.7 mmol) dropwise to a solution of clear magnetic resonance; s, singlet; t, triplet; m, multiplet; brs, broad singlet; Cdk, menadione (5.154 g, 29.9 mmol) and 2-mercaptoethanol (2.10 ml, 29.9 mmol) cyclin-dependent kinase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MS, in 150 ml ether at room temperature. Stirring was maintained at room tem- mass spectrum; GST, glutathione S-transferase; OMFP, o-methyl fluorescein phosphate; perature for 23 h, and then 20 ml of 3.6 M HCl were added. The organic and ts, temperature sensitive; PTP1B, protein tyrosine phosphatase 1B; SC-␣␣␦9, 4-(benzyl- (2-[(2,5-diphenyl-oxazole-4-carbonyl)-amino]-ethyl)-carbamoyl)-2-decanoylamino bu- aqueous phases were separated, and the aqueous layer was extracted with tyric acid; Rb, retinoblastoma; VHR, vaccinia H1-related phosphatase. ether. The combined organic layers were dried over magnesium sulfate, 1317 Downloaded from cancerres.aacrjournals.org on September 28, 2021. © 2000 American Association for Cancer Research. Cdc25 PHOSPHATASE INHIBITION BY VITAMIN K ANALOGUE carbonate (2.40 g, 22.6 mmol) and 30% hydrogen peroxide (10 ml, 97.9 mmol) in water (50 ml) was added together to a solution of menadione (10.168 g, 59.1 mmol) in warm ethanol (110–135 ml). The yellow quinone color disappeared, and the flask was then cooled in ice. Water was added (300 ml) to give 16.334 g of a white solid; melting point 87°C. 1.076 g of this solid was dissolved in concentrated sulfuric acid (6 ml), giving a deep red solution. The flask was swirled intermittently for 10 min, and then water (20 ml) was added slowly to give a yellow precipitate. The mixture was filtered, and the filtercake was washed with water until the filtrate was no longer acidic. This procedure afforded 0.724 g (67%) of Cpd 22; melting point 170–171°C. 1H NMR ␦ 3 (CDCl3) 8.15–8.07 (m, 2H), 7.79–7.66 (m, 2H), 7.3 (s, 1H), 2.12 (s, [ H]); 13 C NMR (CDCl3) 185.08, 181.23, 153.21, 134.89, 132.96, 129.47, 126.78, 126.18, 120.60, 8.74; IR (KBr) cmϪ1 3312 (brs), 1643 (s), 1579 (m); UV (ethanol) ␭max (log ⑀) 206 (4.54), 242 (4.48), 252 (4.47), 276 (4.65); MS (m/z): 188 (100), 160 (30), 132 (42), 105 (33), 77 (35); high resolution MS: calculated for C11H8O3: 188.0473442, found: 188.049347. To synthesize Cpd 16, we added a solution of Cpd 22 (0.713 g, 3.793 mmol) in dry THF (4 ml) via cannula to a suspension of potassium hydride (0.229 g, 5.711 mmol) in dry THF (10 ml) at 0°C. The resulting dark brown mixture was stirred for 5–10 min when a solution of 18-Crown-6 (1.542 g, 5.841 mmol) in dry THF (4 ml) was added.
Load more

Recommended publications
  • 9. Atypical Dusps: 19 Phosphatases in Search of a Role
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Digital.CSIC Transworld Research Network 37/661 (2), Fort P.O. Trivandrum-695 023 Kerala, India Emerging Signaling Pathways in Tumor Biology, 2010: 185-208 ISBN: 978-81-7895-477-6 Editor: Pedro A. Lazo 9. Atypical DUSPs: 19 phosphatases in search of a role Yolanda Bayón and Andrés Alonso Instituto de Biología y Genética Molecular, CSIC-Universidad de Valladolid c/ Sanz y Forés s/n, 47003 Valladolid, Spain Abstract. Atypical Dual Specificity Phosphatases (A-DUSPs) are a group of 19 phosphatases poorly characterized. They are included among the Class I Cys-based PTPs and contain the active site motif HCXXGXXR conserved in the Class I PTPs. These enzymes present a phosphatase domain similar to MKPs, but lack any substrate targeting domain similar to the CH2 present in this group. Although most of these phosphatases have no more than 250 amino acids, their size ranges from the 150 residues of the smallest A-DUSP, VHZ/DUSP23, to the 1158 residues of the putative PTP DUSP27. The substrates of this family include MAPK, but, in general terms, it does not look that MAPK are the general substrates for the whole group. In fact, other substrates have been described for some of these phosphatases, like the 5’CAP structure of mRNA, glycogen, or STATs and still the substrates of many A-DUSPs have not been identified. In addition to the PTP domain, most of these enzymes present no additional recognizable domains in their sequence, with the exception of CBM-20 in laforin, GTase in HCE1 and a Zn binding domain in DUSP12.
    [Show full text]
  • Bioinformatics-Based Screening of Key Genes for Transformation of Liver
    Jiang et al. J Transl Med (2020) 18:40 https://doi.org/10.1186/s12967-020-02229-8 Journal of Translational Medicine RESEARCH Open Access Bioinformatics-based screening of key genes for transformation of liver cirrhosis to hepatocellular carcinoma Chen Hao Jiang1,2, Xin Yuan1,2, Jiang Fen Li1,2, Yu Fang Xie1,2, An Zhi Zhang1,2, Xue Li Wang1,2, Lan Yang1,2, Chun Xia Liu1,2, Wei Hua Liang1,2, Li Juan Pang1,2, Hong Zou1,2, Xiao Bin Cui1,2, Xi Hua Shen1,2, Yan Qi1,2, Jin Fang Jiang1,2, Wen Yi Gu4, Feng Li1,2,3 and Jian Ming Hu1,2* Abstract Background: Hepatocellular carcinoma (HCC) is the most common type of liver tumour, and is closely related to liver cirrhosis. Previous studies have focussed on the pathogenesis of liver cirrhosis developing into HCC, but the molecular mechanism remains unclear. The aims of the present study were to identify key genes related to the transformation of cirrhosis into HCC, and explore the associated molecular mechanisms. Methods: GSE89377, GSE17548, GSE63898 and GSE54236 mRNA microarray datasets from Gene Expression Omni- bus (GEO) were analysed to obtain diferentially expressed genes (DEGs) between HCC and liver cirrhosis tissues, and network analysis of protein–protein interactions (PPIs) was carried out. String and Cytoscape were used to analyse modules and identify hub genes, Kaplan–Meier Plotter and Oncomine databases were used to explore relationships between hub genes and disease occurrence, development and prognosis of HCC, and the molecular mechanism of the main hub gene was probed using Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway analysis.
    [Show full text]
  • The Regulatory Roles of Phosphatases in Cancer
    Oncogene (2014) 33, 939–953 & 2014 Macmillan Publishers Limited All rights reserved 0950-9232/14 www.nature.com/onc REVIEW The regulatory roles of phosphatases in cancer J Stebbing1, LC Lit1, H Zhang, RS Darrington, O Melaiu, B Rudraraju and G Giamas The relevance of potentially reversible post-translational modifications required for controlling cellular processes in cancer is one of the most thriving arenas of cellular and molecular biology. Any alteration in the balanced equilibrium between kinases and phosphatases may result in development and progression of various diseases, including different types of cancer, though phosphatases are relatively under-studied. Loss of phosphatases such as PTEN (phosphatase and tensin homologue deleted on chromosome 10), a known tumour suppressor, across tumour types lends credence to the development of phosphatidylinositol 3--kinase inhibitors alongside the use of phosphatase expression as a biomarker, though phase 3 trial data are lacking. In this review, we give an updated report on phosphatase dysregulation linked to organ-specific malignancies. Oncogene (2014) 33, 939–953; doi:10.1038/onc.2013.80; published online 18 March 2013 Keywords: cancer; phosphatases; solid tumours GASTROINTESTINAL MALIGNANCIES abs in sera were significantly associated with poor survival in Oesophageal cancer advanced ESCC, suggesting that they may have a clinical utility in Loss of PTEN (phosphatase and tensin homologue deleted on ESCC screening and diagnosis.5 chromosome 10) expression in oesophageal cancer is frequent, Cao et al.6 investigated the role of protein tyrosine phosphatase, among other gene alterations characterizing this disease. Zhou non-receptor type 12 (PTPN12) in ESCC and showed that PTPN12 et al.1 found that overexpression of PTEN suppresses growth and protein expression is higher in normal para-cancerous tissues than induces apoptosis in oesophageal cancer cell lines, through in 20 ESCC tissues.
    [Show full text]
  • Purification and Characterization of Two Members of the Protein
    PURIFICATION AND CHARACTERIZATION OF TWO MEMBERS OF THE PROTEIN TYROSINE PHOSPHATASE FAMILY: DUAL SPECIFICITY PHOSPHATASE PVP AND LOW MOLECULAR WEIGHT PHOSPHATASE WZB By Paula A. Livingston A Thesis Submitted to the Faculty of The Charles E. Schmidt College of Science in Partial Fulfillment for the Degree of Master of Science Florida Atlantic University Boca Raton, Florida December 2009 i ACKNOWLEDGMENTS The author wishes to thank her thesis advisor, Dr. Stefan Vetter, and the members of her committee, Dr. Estelle Leclerc and Dr. Predrag Cudic, for their advice and support throughout her years at Florida Atlantic University. The author also wishes to thank her family for their unending support and encouragement without which this would not have been possible. The author would also like to thank her nephew and niece, Griffin and Skye, for inspiring her throughout her entire graduate experience. iii ABSTRACT Author: Paula A. Livingston Title: Purification and Characterization of Two Members of the Protein Tyrosine Phosphatase Family: Dual Specificity Phosphatase PVP and Low Molecular Weight Phosphatase WZB Institution: Florida Atlantic University Thesis Advisor: Dr. Stefan W. Vetter Degree: Master of Science Year: 2009 Two protein tyrosine phosphatases, dual specificity phosphatase PVP and low molecular weight phosphatase WZB were purified and characterized. PVP was expressed as inclusion bodies and a suitable purification and refolding method was devised. Enzyme kinetics revealed that p-nitrophenylphosphate and β-naphthyl phosphate were substrates with KM of 4.0mM and 8.1mM respectively. PVP showed no reactivity towards phosphoserine. Kinetic characterization of WZB showed that only p- nitrophenylphosphate was a substrate with no affinity for β-naphthyl phosphate and phosphoserine.
    [Show full text]
  • Lenalidomide Induces Cell Death in an MDS-Derived Cell Line with Deletion of Chromosome 5Q by Inhibition of Cytokinesis
    Leukemia (2010) 24, 748–755 & 2010 Macmillan Publishers Limited All rights reserved 0887-6924/10 $32.00 www.nature.com/leu ORIGINAL ARTICLE Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis A Matsuoka1, A Tochigi1, M Kishimoto1, T Nakahara1, T Kondo1, T Tsujioka1, T Tasaka1, Y Tohyama2 and K Tohyama1 1Department of Laboratory Medicine, Kawasaki Medical School, Okayama, Japan; and 2Division of Biochemistry, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, Hyogo, Japan Myelodysplastic syndromes (MDS) are a group of hematopoietic higher-risk groups with del(5q) that are susceptible to leukemic stem cell disorders characterized by refractory cytopenias transformation.6 Several hematopoiesis-related genes and tumor and susceptibility to leukemic transformation. On a subset of suppressor genes are located at 5q locus, and SPARC,7 MDS patients with deletion of the long arm of chromosome5 8 9 10 11 (del(5q)), lenalidomide exerts hematological and cytogenetic CTNNA1, EGR1, RPS14 and CDC25C are reported as effects, but the underlying pharmacological mechanisms are the candidate genes of MDS with del(5q) or 5q- syndrome. not fully understood. In this study, we have investigated the Lenalidomide, a derivative of thalidomide, is shown to in vitro effects of lenalidomide on an MDS-derived cell line, exert plenty of biological actions including inhibition of MDS-L, which carries del(5q) and complex chromosome angiogenesis,12 suppression of proinflammatory cytokine abnormalities. We found that the growth of MDS-L cells was production such as TNF-a,13 enhancement of T- and NK-cell specifically suppressed mainly by apoptosis, and in addition, 14–16 multinucleated cells were frequently formed and finally died activation.
    [Show full text]
  • Dephosphorylation of Threonine-14 and Tyrosine-15
    Proc. Natl. Acad. Sci. USA Vol. 90, pp. 3521-3524, April 1993 Biochemistry Cdc25M2 activation of cyclin-dependent kinases by dephosphorylation of threonine-14 and tyrosine-15 BYRON SEBASTIAN*t, AKIRA KAKIZUKAt, AND TONY HUNTER* *Molecular Biology and Virology Laboratory and tGene Expression Laboratory, The Salk Institute for Biological Studies, P.O. Box 85800, San Diego, CA 92186; and tDepartment of Biology, University of California at San Diego, La Jolla, CA 92093 Communicated by Renato Dulbecco, January 4, 1993 (receivedfor review December 15, 1992) ABSTRACT Recent evidence has suggested that human in regulating entry into S phase is suggested by reports that cyclin-dependent kinase 2 (CDK2) is an essential regulator of cycin E-associated kinase activity peaks in G1 (23, 24) and cell cycle progression through S phase. CDK2 is known to that overexpression ofcyclin E decreases the length ofG1 and complex with at least two distinct human cyclins, E and A. The diminishes the dependency of proliferating human cells on kinase activity of these complexes peaks in G1 and S phase, growth factors (23). Although both CDK2 and CDC2 asso- respectively. The vertebrate CDC2/cyclin Bi complex is an ciate with cyclin E, the predominant complex appears to be essential regulator of the onset of mitosis and is inhibited by CDK2/cyclin E. A role for CDK2/cyclin A in regulating phosphorylation of CDC2 on Thr-14 and Tyr-15. In vitro, progression through S phase is suggested by observations CDC2/cyclin Bi is activated by treatment with the members of that microinjection of either anti-cyclin A antibodies or the Cdc25 family of phosphatases.
    [Show full text]
  • Multiple Protein Phosphatases Are Required for Mitosis in Drosophila
    Supplemental References S10. Margolis, S.S., Walsh, S., Weiser, D.C., Yoshida, M., Shenolikar, S., and Kornbluth, S. (2003). PP1 control of M phase entry exerted through 14-3-3-regulated Cdc25 dephosphorylation. Embo J 22, 5734-5745. S11. Margolis, S.S., Perry, J.A., Weitzel, D.H., Freel, C.D., Yoshida, M., Haystead, T.A., and Kornbluth, S. (2006). A role for PP1 in the Cdc2/Cyclin B-mediated positive feedback activation of Cdc25. Mol Biol Cell 17, 1779-1789. S12. Axton, J.M., Dombradi, V., Cohen, P.T., and Glover, D.M. (1990). One of the protein phosphatase 1 isoenzymes in Drosophila is essential for mitosis. Cell 63, 33-46. S13. Rogers, E., Bishop, J.D., Waddle, J.A., Schumacher, J.M., and Lin, R. (2002). The aurora kinase AIR-2 functions in the release of chromosome cohesion in Caenorhabditis elegans meiosis. J Cell Biol 157, 219-229. S14. Sassoon, I., Severin, F.F., Andrews, P.D., Taba, M.R., Kaplan, K.B., Ashford, A.J., Stark, M.J., Sorger, P.K., and Hyman, A.A. (1999). Regulation of Saccharomyces cerevisiae kinetochores by the type 1 phosphatase Glc7p. Genes Dev 13, 545-555. S15. Katayama, H., Zhou, H., Li, Q., Tatsuka, M., and Sen, S. (2001). Interaction and feedback regulation between STK15/BTAK/Aurora-A kinase and protein phosphatase 1 through mitotic cell division cycle. J Biol Chem 276, 46219-46224. S16. Ohashi, S., Sakashita, G., Ban, R., Nagasawa, M., Matsuzaki, H., Murata, Y., Taniguchi, H., Shima, H., Furukawa, K., and Urano, T. (2006). Phospho-regulation of human protein kinase Aurora-A: analysis using anti-phospho-Thr288 monoclonal antibodies.
    [Show full text]
  • Identification of Seven Hub Genes As the Novel Biomarkers in Triple
    Identication of Seven Hub Genes as the Novel Biomarkers in Triple-negative Breast Cancer and Breast Cancer Metastasis Huanxian Wu Southern Medical University Huining Lian Southern Medical University Nanfang Hospital Qianqing Chen Southern Medical University Jinlamao Yang Southern Medical University Nanfang Hospital Baofang Ou Southern Medical University Dongling Quan Southern Medical University Lei Zhou Southern Medical University Lin Lv Southern Medical University Minfeng Liu Southern Medical University Nanfang Hospital Shaoyu Wu ( [email protected] ) Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou, Guangdong, 510515, PR China. https://orcid.org/0000-0002- 1247-5295 Research article Keywords: Triple-negative breast cancer, Metastasis, Biomarkers, Prognostic signature Posted Date: October 5th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-73076/v1 Page 1/20 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 2/20 Abstract Background: Breast cancer is one of the most common malignant tumors with the highest morbidity and mortality among women. Compared with the other breast cancer subtypes, Triple-negative breast cancer (TNBC) has a higher probability of recurrence and is prone to distant metastasis. To reveal the underlying disease mechanisms and identify more effective biomarkers for TNBC and breast cancer metastasis. Methods: Gene Ontology and KEGG pathway analysis were used for investigating the role of overlapping differentially expressed genes (DEGs). Hub genes among these DEGs were determined by the protein- protein interactions network analysis and CytoHubba. Oncomine databases were used for verifying the clinical relevance of hub genes.
    [Show full text]
  • Dual-Specificity Phosphatases in Immunity and Infection
    International Journal of Molecular Sciences Review Dual-Specificity Phosphatases in Immunity and Infection: An Update Roland Lang * and Faizal A.M. Raffi Institute of Clinical Microbiology, Immunology and Hygiene, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany * Correspondence: [email protected]; Tel.: +49-9131-85-22979 Received: 15 May 2019; Accepted: 30 May 2019; Published: 2 June 2019 Abstract: Kinase activation and phosphorylation cascades are key to initiate immune cell activation in response to recognition of antigen and sensing of microbial danger. However, for balanced and controlled immune responses, the intensity and duration of phospho-signaling has to be regulated. The dual-specificity phosphatase (DUSP) gene family has many members that are differentially expressed in resting and activated immune cells. Here, we review the progress made in the field of DUSP gene function in regulation of the immune system during the last decade. Studies in knockout mice have confirmed the essential functions of several DUSP-MAPK phosphatases (DUSP-MKP) in controlling inflammatory and anti-microbial immune responses and support the concept that individual DUSP-MKP shape and determine the outcome of innate immune responses due to context-dependent expression and selective inhibition of different mitogen-activated protein kinases (MAPK). In addition to the canonical DUSP-MKP, several small-size atypical DUSP proteins regulate immune cells and are therefore also reviewed here. Unexpected and complex findings in DUSP knockout mice pose new questions regarding cell type-specific and redundant functions. Another emerging question concerns the interaction of DUSP-MKP with non-MAPK binding partners and substrate proteins.
    [Show full text]
  • CDKN3 Mrna As a Biomarker for Survival and Therapeutic Target in Cervical Cancer
    RESEARCH ARTICLE CDKN3 mRNA as a Biomarker for Survival and Therapeutic Target in Cervical Cancer Eira Valeria Barrón1,2, Edgar Roman-Bassaure3, Ana Laura Sánchez-Sandoval4, Ana María Espinosa1, Mariano Guardado-Estrada1, Ingrid Medina1, Eligia Juárez1, Ana Alfaro1, Miriam Bermúdez1, Rubén Zamora5,6, Carlos García-Ruiz1, Juan Carlos Gomora4, Susana Kofman7, E. Martha Pérez-Armendariz2¤, Jaime Berumen1,2* 1 Unidad de Medicina Genómica, Facultad de Medicina, Universidad Nacional Autónoma de México/ Hospital General de México, México City, México, 2 Departamento de Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México, México City, México, 3 Servicio de Oncología, Hospital General de México, México City, México, 4 Departamento de Neuropatología Molecular, División de Neurociencias, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, México City, México, 5 Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, México City, México, 6 Laboratorio de Biología Molecular, Asociación para Evitar la Ceguera en México Hospital Dr. Luis Sánchez-Bulnes, México City, México, 7 Servicio de Genética, Hospital General de México/Facultad de Medicina, Universidad Nacional Autónoma de México, México City, México ¤ Current address: Departamento de Biología, Celular y Tisular, Facultad de Medicina, Universidad Nacional OPEN ACCESS Autónoma de México, México City, México * [email protected] Citation: Barrón EV, Roman-Bassaure E, Sánchez- Sandoval AL, Espinosa AM, Guardado-Estrada M, Medina I, et al. (2015) CDKN3 mRNA as a Biomarker for Survival and Therapeutic Target in Cervical Abstract Cancer. PLoS ONE 10(9): e0137397. doi:10.1371/ CDKN3 journal.pone.0137397 The cyclin-dependent kinase inhibitor 3 ( ) gene, involved in mitosis, is upregulated in cervical cancer (CC).
    [Show full text]
  • PTEN Enhances G2/M Arrest in Etoposide-Treated MCF-7 Cells
    ONCOLOGY REPORTS 35: 2707-2714, 2016 PTEN enhances G2/M arrest in etoposide-treated MCF-7 cells through activation of the ATM pathway RUOPENG ZHANG1,2, LI ZHU2, LIRONG ZHANG2, ANLI XU2, ZHENGWEI LI3, YIJUAN XU3, PEI HE3, MAOQING WU4, FENGXIANG WEI5 and CHENHONG Wang1 1Department of Obstetrics and Gynecology, Shenzhen Maternity and Child Healthcare Hospital, Affiliated to Southern Medical University, Longgang, Shenzhen, Guangdong 518028; 2Department of Reproductive Medicine, Affiliated Hospital of Dali University, Dali, Yunnan 671000;3 Clinical Medicine College of Dali University, Dali, Yunnan 671000, P.R. China; 4Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; 5The Genetics Laboratory, Shenzhen Longgang District Maternity and Child Healthcare Hospital, Longgang, Shenzhen, Guangdong 518028, P.R. China Received November 19, 2015; Accepted December 27, 2015 DOI: 10.3892/or.2016.4674 Abstract. As an effective tumor suppressor, phosphatase and role in etoposide-induced G2/M arrest by facilitating the acti- tensin homolog (PTEN) has attracted the increased attention of vation of the ATM pathway, and PTEN was required for the scientists. Recent studies have shown that PTEN plays unique proper activation of checkpoints in response to DNA damage roles in the DNA damage response (DDR) and can interact in MCF-7 cells. with the Chk1 pathway. However, little is known about how PTEN contributes to DDR through the ATM-Chk2 pathway. It Introduction is well-known that etoposide induces G2/M arrest in a variety of cell lines, including MCF-7 cells. The DNA damage-induced Cellular DNA is constantly challenged by either endogenous G2/M arrest results from the activation of protein kinase [reactive oxygen species (ROS)] or exogenous (UV) factors.
    [Show full text]
  • A Novel Synthetic Inhibitor of CDC25 Phosphatases: BN82002
    [CANCER RESEARCH 64, 3320–3325, May 1, 2004] A Novel Synthetic Inhibitor of CDC25 Phosphatases: BN82002 Marie-Christine Brezak,1 Muriel Quaranta,2 Odile Monde´sert,2 Marie-Odile Galcera,1 Olivier Lavergne,1 Fre´de´ric Alby,2 Martine Cazales,2 Ve´ronique Baldin,2 Christophe Thurieau,1 Jeremiath Harnett,1 Christophe Lanco,1 Philip G. Kasprzyk,1,3 Gregoire P. Prevost,1 and Bernard Ducommun2 1IPSEN, Institut Henri Beaufour, Les Ulis Cedex, France; 2Laboratoire de Biologie Cellulaire et Moleculaire du Controle de la Proliferation-Centre National de la Recherche Scientifique UMR5088-IFR109 “Institut d’Exploration Fonctionnelle des Ge´nomes,” Universite´ Paul Sabatier, Toulouse, France; and 3IPSEN, Biomeasure, Milford, Massachusetts ABSTRACT B at mitosis (2) where it dephosphorylates tyrosine 15 and threonine 14. It also plays a role in the control of the initiation of S phase (5). CDC25 dual-specificity phosphatases are essential regulators that de- The elucidation of the specific role of each isoform at specific stages phosphorylate and activate cyclin-dependent kinase/cyclin complexes at of the cell cycle is a major issue that is still currently under investi- key transitions of the cell cycle. CDC25 activity is currently considered to be an interesting target for the development of new antiproliferative gation. agents. Here we report the identification of a new CDC25 inhibitor and Overexpression of CDC25A and B, but not C, has been observed in the characterization of its effects at the molecular and cellular levels, and a variety of cancers (i.e., breast, ovary, head and neck, and colon) with in animal models. a striking association with tumor aggressiveness and poor prognosis BN82002 inhibits the phosphatase activity of recombinant human (6–9).
    [Show full text]